



Classification of Focus
● Active foci

I. Epidemiological profile

Population (UN)	2015	%
Number of active foci	11	
Number of people living within active foci	23,900	6
Malaria-free (0 cases)	360,000	94
Total	360,000	

Parasites and vectors

Plasmodium species:	<i>P. falciparum</i> (0%), <i>P. vivax</i> (100%)		
Major anopheles species:	<i>An. albimanus</i> , <i>An. darlingi</i>		
Reported confirmed cases (health facility):	9	Estimated cases:	<50
Confirmed cases at community level:	-		
Reported deaths:	0	Estimated deaths:	<50[-;-]

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/ LLINs distributed free of charge	Yes	2009
	ITNs/ LLINs distributed to all age groups	Yes	2009
IRS	IRS is recommended	Yes	-
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	Yes	-
Treatment	ACT is free of charge for all ages in public sector	Yes	2010
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	-
	System for monitoring adverse reactions to antimalarials exists	No	-
Surveillance	ACD for case investigation (reactive)	Yes	-
	ACD of febrile cases at community level (pro-active)	Yes	-
	Mass screening is undertaken	Yes	-
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-
	Foci and case investigation undertaken	Yes	-
Case reporting from private sector is mandatory	Yes	-	

Antimalarial treatment policy

	Medicine	Year adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of <i>P. falciparum</i>	CQ+PQ(1d)	-
Treatment failure of <i>P. falciparum</i>	QN	-
Treatment of severe malaria	AL; QN	-
Treatment of <i>P. vivax</i>	CQ+PQ(14d)	-
Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)
Type pf RDT used		-

Therapeutic efficacy tests (clinical and parasitological failure, %)


Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
-							

Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)


Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested
2010-2014					

III. Financing

Sources of financing




Government expenditure by intervention in 2015




IV. Coverage

Coverage of ITN and IRS




Cases tested




V. Impact


Cases treated



Test positivity



Confirmed malaria cases per 1000 and ABER



Number of malaria cases

